中国肺癌杂志2025，Vol.28Issue(8)：597-611,15.DOI:10.3779/j.issn.1009-3419.2025.101.13
KRASG12C突变非小细胞肺癌诊断及靶向治疗进展
Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer
摘要
Abstract
Lung cancer stands as the primary cause of cancer-related mortalities globally,presenting a severe men-ace to human health.In individuals with non-small cell lung cancer(NSCLC),Kirsten rat sarcoma viral oncogene(KRAS)mu-tations serve as crucial oncogenic drivers.NSCLC with KRASG12C mutation is among the most prevalent subtypes.Currently,the detection methods for KRAS mutations predominantly concentrate on polymerase chain reaction(PCR)and sequencing platforms.The diverse derivative technologies of these two platforms each exhibit distinct merits and demerits in terms of testing performance and detection throughput,and find significant applications in tissue biopsy and liquid biopsy.In targeted therapies,KRASG12C targeted drugs,including Sotorasib,Adagrasib,Fulzerasib,Garsorasib,and Glecirasib,have demonstrated certain therapeutic efficacies in clinical trials and have obtained marketing approval.To tackle drug resistance and enhance patient's prognoses,combination therapeutic strategies that integrate targeted agents with chemotherapy,immune checkpoint inhibitors,Src homology region 2 domain-containing phosphatase 2(SHP2)inhibitors,and epidermal growth factor recep-tor(EGFR)monoclonal antibodies have emerged.This paper systematically reviews the advancements in the diagnosis and targeted therapy of NSCLC with KRASG12C mutation,aiming to offer a reference for the selection of clinical treatment regimens and subsequent research.关键词
Kirsten鼠类肉瘤病毒癌基因/肺肿瘤/基因检测/靶向治疗Key words
Kirsten rat sarcoma viral oncogene/Lung neoplasms/Genetic testing/Targeted therapy引用本文复制引用
石嘉和,王雨芳,郑静,周建娅..KRASG12C突变非小细胞肺癌诊断及靶向治疗进展[J].中国肺癌杂志,2025,28(8):597-611,15.基金项目
This paper was supported by the grants from Key R&D Program of Zhejiang Respiratory Disease(No.2023C03069)(to Jianya ZHOU)and the"Top Soldier"and"Leading Wild Goose"R&D Project of Zhejiang(No.2025C02092)(to Jing ZHENG). 本文受浙江省呼吸系统疾病重点研发计划项目(No.2023C03069)和浙江省科学技术厅"尖兵领雁+X"科技计划项目(No.2025C02092)资助 （No.2023C03069）
